FBIOP sentiment intelligence

Fortress Biotech Inc (FBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Fortress Biotech Inc (FBIO), highlighting its current earnings forecast score of 8.00 within the Pharmaceuticals industry. Analysts have set an average price target of $10.75 for FBIO, with a "Buy" trend based on two analyst ratings.

FORTRESS BIOTECH INC 9.375% Cumulative Redeemable Preferred Stock Series A USD25.00 (FBIOP.US) will release its earnings report after market close on August 12.

Fortress Biotech (FBIO) to Release Earnings on Thursday

Fortress Biotech (FBIO) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 13th, with analysts expecting a loss of $0.20 per share on revenue of $18.30 million. The company's previous quarter significantly beat EPS estimates but slightly missed re

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO)

Levi & Korsinsky, LLP has launched an investigation into Fortress Biotech, Inc. (NASDAQ: FBIO) regarding potential breaches of fiduciary duties by its officers and directors. Current FBIO shareholders are encouraged to seek additional information or contact Joseph E. Levi, Esq. t

FBIO|Fortress Biotech Inc|Price:3.301|Chg%:-0.049

This article provides a comprehensive stock analysis of Fortress Biotech Inc (FBIO), highlighting its strong fundamentals, high growth potential, and "fairly valued" status within the Pharmaceuticals industry. It notes high institutional ownership and a "Buy" rating from multiple

Press Release: Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing

Fortress Biotech and its subsidiary Urica Therapeutics announced that Crystalys Therapeutics, a clinical-stage biotechnology company, has successfully completed a $130 million Series B financing round. Urica Therapeutics has an equity ownership stake in Crystalys Therapeutics, be

Fortress Biotech Inc (FBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Fortress Biotech Inc (FBIO) by business segment. As of April 2, 2025, the company's products Targadox®, Exelderm®, and Ximino® generated revenues of $3.20M, $2.40M, and $287.00K respectively, comprising 3.79%, 2.83%, and 0.34% of the

Fortress Biotech Inc (FBIO) Institutional Confidence

Fortress Biotech Inc (FBIO) has an institutional shareholding score of 3.00, ranking 92nd out of 155 in the Pharmaceuticals industry. The current institutional shareholding proportion is 18.14%, reflecting a 31.58% decrease quarter-over-quarter. James Simons is the largest instit

Fortress Biotech Inc (FBIO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Fortress Biotech Inc (FBIO), listing major individual and institutional holders. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with changes in holdi

Fortress Biotech, Inc. Revenue Breakdown – NASDAQ:FBIO

Fortress Biotech, Inc. (NASDAQ: FBIO) generated $63.26 million in revenue last year, with its Journey segment contributing the most at $61.86 million. The United States was the primary source of revenue, accounting for the entire $63.26 million. This shows a slight increase in ov

Fortress Biotech Inc (FBIO) Income Statement

This article provides an income statement for Fortress Biotech Inc (FBIO), detailing its quarterly and annual financial performance. It includes metrics such as total revenue, cost of revenue, operating expenses, and net income, alongside year-over-year comparisons. The page also

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

This article provides details on the revenue breakdown for Fortress Biotech, Inc.'s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP). Last year, the company generated $63.26 million USD in total revenue, with its Journey segment contributing $61.86 million

Fortress Biotech Inc (FBIO) Financial Health: Profitability & Balance Sheet Analysis

Fortress Biotech Inc (FBIO) has a robust financial score of 8.91, ranking 26 out of 155 in the Pharmaceuticals industry, indicating strong financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 22.06% and a net profit

FBIO|Fortress Biotech Inc|Price:3.340|Chg%:-0.090

Fortress Biotech Inc (FBIO) is trading at $3.34, down 2.62%. The company's fundamentals are considered healthy with high growth potential, and its valuation is seen as fairly valued within the Pharmaceuticals industry. Analysts have rated it a "Buy" with a target price of $11.00,

Biotech stocks lead healthcare's overbought list as earnings picks up (XLV:NYSEARCA)

Fortress Biotech Preferred Stock (FBIOP) Holds Steady Near Support Amid Low Volume Trading - Synthetic Short

Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks

CNB0 Bond Coupon Profile — Rate & Payments

This article provides a brief overview of the CNB0 bond coupon profile, detailing its interest rate and payment structure. It highlights the importance of the coupon as the interest rate paid on a bond by Fortress Biotech, Inc. for its 9.375% Series A Cumulative Redeemable Perpet

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Fortress Biotech highlights its biotech portfolio strategy as a Nasdaq-listed micro-cap

Fortress Biotech, a Nasdaq-listed biopharmaceutical company, emphasizes its strategy of a diversified portfolio managed through subsidiary companies and partnerships. This approach focuses on licensing, clinical development, and eventual commercialization of novel therapeutics, p

Mustang Bio (MBIO) Registration Filing Summary

Mustang Bio (MBIO) is a clinical-stage biopharmaceutical company focused on CAR T therapies, operating as a majority-controlled subsidiary of Fortress Biotech. The company has an accumulated deficit of $395.8 million, no product sales to date, and faces significant doubt about it

Fortress Biotech focuses on specialty pharma growth and licensing model

Fortress Biotech pursues a portfolio strategy in specialty pharmaceuticals, building and licensing therapies through its partner companies, and diversifying its pipeline to mitigate risk. The company focuses on specialty and rare disease markets, aiming for premium pricing and st

Fortress Biotech Inc highlights its specialty pharma model as investors assess long-term prospects

Fortress Biotech Inc operates a specialty pharmaceutical and biotech portfolio strategy, utilizing a holding-style structure with multiple subsidiaries to develop product candidates across various disease areas like oncology and rare diseases. This approach aims to diversify risk